

CLEAN VERSION OF EACH REPLACEMENT PARAGRAPH/SECTION/CLAIM AND
INSTRUCTIONS FOR ENTRY

IN THE SPECIFICATION:

A1

As a result of these procedures, the disease specific markers Actin beta having a molecular weight of about 1198.7061 daltons and having a sequence identified as SEQ ID NO: 1, complement C3 precursor having a molecular weight of about 1969.9355 daltons and a sequence identified as SEQ ID NO: 2, proapolipoprotein having a molecular weight of about 1301.6490 daltons and a sequence identified as SEQ ID NO: 3, apolipoprotein A-IV precursor, having a molecular weight of about 1353 and SEQ ID NO: 4 and a molecular weight of about 1104 and SEQ ID NO: 5. predictive of Type II diabetes.

IN THE CLAIMS:

A2

1. A biopolymer marker selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or at least one analyte thereof useful in indicating at least one particular disease state.

A3

18. A kit for diagnosing, determining risk-assessment, and identifying therapeutic avenues related to a disease state comprising:

at least one biochemical material which is capable of specifically binding with a biomolecule which includes at least one biopolymer marker selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or at least one